ABSK061

DRUG3 trials

Sponsors

Abbisko Therapeutics Co, Ltd

Conditions

AchondroplasiaHealthySolid Tumor

Phase 1

A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors

RecruitingNCT05244551

Abbisko Therapeutics Co, LtdSolid Tumor

Start: 2022-06-30End: 2025-04-30Target: 85Updated: 2024-08-12

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABSK061 Mini-tablets in Healthy Adult Participants

CompletedNCT07007546

Abbisko Therapeutics Co, LtdHealthy

Start: 2025-05-17End: 2026-04-14Updated: 2026-06-29

A Study of ABSK061 to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy in Children With Achondroplasia

Not yet recruitingNCT07297875

Abbisko Therapeutics Co, LtdAchondroplasia

Start: 2025-12-10End: 2031-03-15Target: 110Updated: 2025-12-22

Related Papers

Abstract 5319: Circulating tumor DNA (ctDNA)-based profiling of acquired resistance to the fibroblast growth factor receptor (FGFR)2/3 inhibitor lavengratinib(ABSK061) in patient(pt)s with advanced solid tumors.

Cancer Research2026-04-03

45O First-in-human study of ABSK061: A selective fibroblast growth factor receptor (FGFR) 2/3 inhibitor for treating patients with advanced solid tumors

ESMO Open2024-02-011 citations